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AIDS	 	 	 	 Acquired	immune	deficiency	syndrome	
CI	 	 	 	 Confidence	Interval	
DNA	 	 	 	 Deoxyribonucleic	Acid	
ESR	 	 	 	 Erythrocyte	Sedimentation	Rate	
GeneXpert	 	 	 Xpert	MTB/RIF,	Xpert	
HIV	 	 	 	 Human	Immunodeficiency	Virus	
LPA	 	 	 	 Line	Probe	Assay	
MDR	 	 	 	 Multi-drug	resistance	
N	 	 	 	 Number	
PCR	 	 	 	 Polymerase	Chain	Reaction	
PTB	 	 	 	 Pulmonary	TB	
TB	 	 	 	 Tuberculosis	
WHO	 	 	 	 World	Health	Organization	






































































to	 prevent	 joint	 destruction,	 growth	 arrest,	 and	 contractures	 in	 large	 joints	 as	 well	 as	
deformity	 with	 neurological	 compromise	 in	 spinal	 disease,	 which	 may	 lead	 to	 lifelong	
morbidity	 and	 disability.21-25	 The	 current	 gold	 standard	 to	 test	 for	 osteoarticular	 TB	 is	
mycobacterial	 culture	 and	histology.26	 For	 pulmonary	 samples,	 a	meta-analysis	 reported	 a	
time	to	detection	of	22	(smear	positive)	to	34	(smear	negative)	days	in	Loewenstein-Jensen	
medium	 and	 12	 (smear	 positive)	 to	 18	 days	 (smear	 negative)	 in	 radiometric	 Bactec	 460	
medium.	The	sensitivity	and	specificity	in	detecting	pulmonary	TB	with	BACTEC	460	systems	
is	87.7	and	89.7%,	respectively.27	However,	joint	biopsy	samples	usually	contain	only	a	small	
number	 of	 bacteria,	 making	 culture	 and	 staining	 for	 acid-fast	 bacilli	 challenging.15,	 28	 The	
sensitivity	of	TB	culture	(Loewenstein-Jensen	medium)	compared	to	a	composite	reference	
standard	for	childhood	musculoskeletal	TB	is	approximately	73%	(70%	in	hips,	71%	in	knees,	

















The	 Foundation	 for	 Innovative	 New	 Diagnostics	 (FIND)	 has	 collaborated	 with	 an	 industry	
partner	(Cepheid,	Sunnyvale,	CA)	to	develop	Xpert®	MTB/RIF.		Further	funding	was	provided	
by	 the	 US	 National	 Institutes	 of	 Health.	 The	 laboratory	 of	 Professor	 David	 Alland	 at	 the	
University	 of	 Medicine	 and	 Dentistry	 in	 New	 Jersey	 provided	 technical	 support.	 	 Xpert	
MTB/RIF	(Xpert)	carries	a	registered	trademark	and	is	manufactured	by	Cepheid.	
The	Xpert	assay	is	a	cartridge	based,	automated,	in	vitro	form	of	a	NAAT	(Figure	3).	The	system	








cost-intensive	 laboratory	 set-up	 necessary	 for	 non-automated	 NAATs.	 It	 is	 therefore	 an	
















































For	 childhood	 PTB	 at	 Red	 Cross	 Children’s	 Hospital,	 the	 sensitivity	 of	 Xpert	 on	 repeated	
induced	sputum	specimens	compared	to	liquid	culture	is	approximately	70%58	and	in	a	recent	
meta-analysis59	 the	 pooled	 sensitivity	 of	 a	 single	 Xpert	 was	 62%.	 Another	meta-analysis60	
reported	that	Xpert	had	moderate	sensitivity	and	high	specificity	of	65%	(95%	CI:	61	-	69%)	
and	 99%	 (95%	 CI:	 98	 -	 99%),	 respectively	 for	 childhood	 pulmonary	 TB.	 Sensitivity	 and	
specificity	for	paediatric	rifampicin	resistance	were	94.0%	(95%	CI:	80.0	-	93.0%)	and	99.0%	
(95%	CI:	95.0	-	98.0%),	respectively.		
Similar	 findings	 have	 recently	 been	 confirmed	 by	 a	 large	 multicentre	 trial61	 reporting	 a	
sensitivity	of	68%	(95%	CI,	50%-82%)	and	specificity	of	100%	(95%	CI,	97%-100%)	in	children	
with	suspected	pulmonary	TB	when	compared	with	culture.	Xpert	detected	1.7	times	more	
culture-confirmed	cases	 than	smear	microscopy	with	a	 similar	 time	 to	detection.	 	Another	











for	 adult	 tissue	 samples	 of	 various	 origins,	 the	 sensitivity	 varied	widely	 between	42%	and	





Rifampicin	 resistance	 occurs	 most	 commonly	 via	 mutation	 of	 the	 rpoB	 gene	 encoding	 a	
subunit	of	 the	bacterial	RNA	polymerase,	which	 is	 the	binding	site	 for	 the	antibiotic.64	The	
Xpert	does	not	detect	resistance	to	any	other	antibiotics	(multidrug	resistance)	used	to	treat	
TB	and	therefore	culture	is	still	recommended.	A	line	probe	assay	(LPA),	is	a	DNA	strip	test,	




Current	 evidence	 supports	 the	 accuracy	 of	 Xpert	 to	 detect	 resistance	 to	 rifampicin.	 	 Its	
sensitivity	and	specificity	in	adults	for	pulmonary	TB	is	high	(95%	and	98%	respectively).	39	In	
a	meta-analysis,	data	on	resistance	testing	 in	tissue	was	available	for	566	samples	from	13	





















Standard	 Design	 Age	 N	 Type	
Monni	
2012	65	 72		(82	in	HIV)	 100	 100	 67	 not	done	 Clinico-radiologic	signs	 prospective	 adults	 29	 tissue	
Gu	


























































































Specimens	 were	 submitted	 in	 sterile	 saline	 in	 duplicate	 to	 the	 mycobacterial	 culture	























































































































































































































































































	 Overall	 Definite	TB	 Probable	TB	 Not	TB		 P	value	
N	 69	 36	 8	 26	 0.28	
HIV		+	 22	(31.9%)	 13	(36.1%)	 4	(50.0%)	 5	(20.0%)	 0.28	
Sex	(male)	 31	(44.9%)	 14	(38.9%)	 6	(75.0%)	 11	(44.0%)	 0.18	
Age	-Median	(IQR)	 40	(27	-	60)	 31	(27	-	46)	 37.5	(23	-	57.5%)	 51	(40	-	63)	 0.06	




Reference	Standard	 All	(N)	 Sensitivity	%	(N)	 Specificity	%	(N)	 PPV	%	(N)	 NPV	%	(N)	
TB	Culture	or	histology	
positive	
71	 95.6%	(44/46)	 96.2%	(25/26)	 97.7%(44/45)	 92.6%	(25/27)	
TB	Culture	positive	
only	

































































adults.56	 In	a	 second	meta-analysis	of	 the	accuracy	of	Xpert	on	 tissue	 samples	 (other	 than	
lymph	 nodes)	 using	 culture	 as	 a	 reference	 standard39	 the	 reported	 pooled	 sensitivity	was	
81.2%	(95%	CI,	67.7	–	89.0%)	and	specificity	was	98.1%	(95%	CI,	87.0	–	99.8%).	However,	there	
are	no	large	published	studies	on	the	accuracy	of	Xpert	for	musculoskeletal	disease	in	either	























































































































































































positive only  
TB Culture negative 
but histology positive  
Not TB  P value 
N (%) of patients 201 75 (37.3) 15 (7.5) 111 (55.2)  
HIV infected 
HIV uninfected 















Sex (male) 97 (48.3) 33 (44.0) 9 (60.0) 55 (49.6) 0.485 







Spine 122 59.2 
Hip 10 4.8 
Knee 30 14.6 
Ankle and foot 9 4.4 
Shoulder 6 2.9 
Elbow 5 2.4 
Wrist/Hand 3 1.5 
Bone 20 9.7 
Sacroiliac joint 1 0.5 
Total 206 100 









TB culture or histology 
positive (N = 84) 
All (N) 
samples 
Sensitivity % (N) 
CI 95% 
Specificity % (N) 
CI 95% 
PPV % (N) 
CI 95% 
NPV % (N) 
CI 95% 
TB Culture  76/206 
(36.9%) 
76/91 
83.5 (74.3 – 90.5) 
115/115 
100 (96.8 – 100) 
76/76 
100.0 (95.2 – 100) 
115/130 




92.3 (84.8 – 96.9) 
114/115 
99.1 (95.2 – 99.8) 
84/85 
98.8 (93.6 – 99.8) 
114/121 
94.2 (88.4 – 97.6) 




33.7 (24.2 – 44.3) 
110/112 
99.1 (95.8 – 99.9) 
31/32 
96.9 (83.8 – 99.9) 
110/171 
64.3 (56.7 – 71.5) 
N = number of patients. PPV = positive predictive value. NPV = Negative predictive value. AFB = evidence of acid fast bacilli 













Xpert resistant  4 0 0 2 6 
Xpert sensitive  0 64 1 13 78 
Xpert Inconclusive 0 1 0 0 1 
Xpert negative 0 7 0 114 121 














































75 1 5 41 
75/80 
93.8  
(86.0 – 97.9) 
41/42 
97.6  










9 0 2 73 
9/11 
81.8  
(48.2 – 97.7) 
73/73 
100  







P-value      0.164 0.186 0.729 0.061 






















31 0 1 14 
31/32 
96.9  
(83.8 – 99.9) 
14/14 
100  











10 0 1 43 
10/11 
90.9  
(58.7 – 99.8) 
43/43 
100  





































































































































































































































Site Number (%) 
Spine 14 (12.8) 
Hip 18 (16.5) 
Knee 48 (44.0) 
Ankle and foot 11 (10.1) 
Shoulder 3 (2.7) 
Elbow 6 (5.5) 
Wrist/Hand 1 (1.0) 
Bone 8 (7.3) 
Sacroiliac joint 0 (0.0) 










Not TB  P value 
N (%) of patients 102 13 (12.8%) 9 (8.8%) 80 (78.4%)  
Sex (male) 60 (58.8%) 7 (53.9%) 3/9 (33.3) 50/80 (62.5) 0.224 
Median age (months) 
IQR  
66.8  
(26.1 – 104.0) 
51.1 
(40.7 – 82.9) 
60.2 
(48.6 – 121.1) 
68.3 
(22.1 – 109.7) 
0.479 






*one AFB not done N=108 
 N = number of patients, PPV = positive predictive value, NPV = Negative predictive value. AFB = evidence of acid fast bacilli 




 Time to result (CI 95%) Time to positive result (CI 95%) Time to negative result (CI 95%) 
Xpert 0.8 (0.5 – 1.4) 0.8 (0.3 – 1.9) 0.7 (0.5 – 1.4) 
Culture 44 (43 – 45) 21.5 (19 – 30) 44 (43 – 46) 
















Xpert resistant  0 0 0 0 0 
Xpert sensitive  0 9 1 7 17 
Xpert inconclusive 0 0 0 0 0 
Xpert negative 1 2 1 88 92 





All (N) samples Sensitivity % (N) 
CI 95% 
Specificity % (N) 
CI 95% 
PPV % (N) 
CI 95% 
NPV % (N) 
CI 95% 
Xpert 17 (15.6%) 17/23 
73.9 (51.6 – 89.8) 
86/86 
100.0 (95.7 – 100.0) 
17/17 
100.0 (81.6 – 100.0) 
86/92 
93.5 (86.3 – 97.6) 
AFB only* 15 (13.8%) 15/23 
65.2 (42.7 – 83.6) 
85/85 
100.0 (95.4 – 100.0) 
15/15 
100.0 (79.6 – 100.0) 
85/93 
91.4 (83.8 – 96.2) 
Histology 23 (21.9%) 23/23 
100.0 (85.7 – 100.0) 
82/82 
100.0 (95.5 – 100.0) 
23/23 
100.0 (85.7 – 100.0) 
82/82 


































































































































































































































	 	 	 	 	 	 	 	 	 12.2.16	
				Dr	Michael	Held	–	primary	author	 	 	 	 	 	 							Date	
	 	 	 	 	 	 	 	 	 14.2.16	
				Prof	Robert	Dunn	–	Supervisor	 	 	 	 	 	 								Date	
	 	 	 	 	 	 	 	 	 	 	










































































































































































































































































































































The	doctors	who	are	also	 involved	 in	treating	your	medical	condition.	 	Any	additional	staff	
involved	 (Research	 assistance,	 statisticians)	 with	 the	 research	 project	 will	 see	 your	 data	
WITHOUT	your	personal	details.			
	
Who	has	allowed	this	research	to	take	place?	
	
Our	departmental	research	committee	and	the	local	ethics	committee	have	looked	carefully	
at	this	work	and	agreed	that	the	research	is	important,	that	it	will	be	conducted	properly	and	
participants’	safety	and	rights	have	been	respected.	
	
What	if	I	have	any	questions?	
You	may	ask	any	of	our	staff	questions	at	any	time.		The	principle	investigator	of	this	study	is:	
Prof.	Robert	Dunn,	Head:	Division	of	Orthopaedic	Surgery,	Spine	Deformity	Service	Red	Cross	
Children's	Hospital	
Secretaries:	University	of	Cape	Town,	Mrs	Priest,	tel.		021	404	5108		
	
If	you	want	to	ask	someone	independent	anything	about	this	research	please	contact	
If	you	have	any	questions,	concerns	or	complaints	about	this	research	study,	its	procedures,	
risks	and	benefits,	or	alternative	courses	of	treatment,	you	should	ask	the	Chairperson	of	the	
Human	Research	Ethics	Committee,	Prof	Blockman:	021	406	6492.	
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